Related Experiment Videos

Hypertriglyceridemia: a review beyond low-density lipoprotein

Richard J Rapp1

  • 1Little Rock Diagnostic Clinic, Little Rock, Arkansas 72205, USA.

Insights

Elevated triglycerides play a key role in atherosclerosis development, contributing to coronary artery disease risk. Detailed lipid analysis is crucial for aggressive hypertriglyceridemia management and identifying at-risk patients.

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Atherosclerosis Research

Background:

  • Hypertriglyceridemia is a complex dyslipidemia often associated with low high-density lipoprotein cholesterol.
  • The independent predictive value of triglycerides in coronary artery disease (CAD) is debated due to particle diversity and confounding factors.
  • Recent evidence highlights the primary role of triglycerides in atherogenesis.

Purpose of the Study:

  • To re-evaluate the role of elevated triglycerides in coronary artery disease.
  • To emphasize the atherogenic potential of triglyceride-rich lipoproteins (TRLs) and altered low-density lipoprotein (LDL) phenotypes.
  • To advocate for more comprehensive lipid analysis in managing hypertriglyceridemia.

Main Methods:

  • Review of recent data on triglyceride metabolism and atherosclerosis.
  • Analysis of the impact of cholesterol ester transfer protein (CETP) on TRLs.
  • Examination of LDL particle size and density in hypertriglyceridemia states.

Main Results:

  • Triglyceride-rich lipoprotein particles, especially those enriched with cholesterol via CETP, are highly atherogenic.
  • Hypertriglyceridemia is associated with the atherogenic small, dense LDL phenotype (Pattern B), increasing CAD risk threefold.
  • This small, dense LDL phenotype is not detected by routine lipid testing.

Conclusions:

  • Elevated triglycerides are a primary driver of atherosclerosis, not merely a statistical correlate.
  • Aggressive management of hypertriglyceridemia necessitates detailed lipid profiling beyond standard tests.
  • Broader risk assessment including triglycerides can expand eligibility for lipid-lowering therapies, benefiting more patients at risk for CAD.

Related Concept Videos